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Glycemic control among patients with prediabetes and type 2 diabetes mellitus (T2D) inMalaysia is suboptimal, especially after the
continuous worsening over the past decade. Improved glycemic control may be achieved through a comprehensive management
strategy that includes medical nutrition therapy (MNT). Evidence-based recommendations for diabetes-specific therapeutic diets
are available internationally. However, Asian patients with T2D, including Malaysians, have unique disease characteristics and
risk factors, as well as cultural and lifestyle dissimilarities, which may render international guidelines and recommendations less
applicable and/or difficult to implement. With these thoughts in mind, a transcultural Diabetes Nutrition Algorithm (tDNA) was
developed by an international task force of diabetes and nutrition experts through the restructuring of international guidelines for
the nutritional management of prediabetes and T2D to account for cultural differences in lifestyle, diet, and genetic factors. The
initial evidence-based global tDNA template was designed for simplicity, flexibility, and cultural modification. This paper reports
theMalaysian adaptation of the tDNA,which takes into account the epidemiologic, physiologic, cultural, and lifestyle factors unique
to Malaysia, as well as the local guidelines recommendations.
1. Introduction
Globally, the prevalence of prediabetes and type 2 diabetes
(T2D) is increasing as a consequence of social, epidemiologic,
and demographic shifts, such as population aging and urban-
ization [1, 2]. The majority of people with these conditions
now live in low- and middle-income countries, including
many Asian nations, where substantial increases in incidence
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rates are anticipated by the year 2030 [2]. According to
the fourth Malaysian National Health and Morbidity Survey
(NHMS IV) carried out in 2011, the prevalence of T2D in
Malaysian adults≥30 years of age had risen to 20.8%, affecting
an estimated 2.8 million individuals [3] as compared with
the third National Health andMorbidity Survey (NHMS III),
which reported a prevalence of 14.9% in 2006 [4].The hetero-
geneous nature of Asian populations gives rise to unique T2D
features. For example, Asians tend to develop T2D at a lower
body mass index (BMI), at younger age, and with a lower
waist circumference than Caucasians [5, 6], and their course
of illness is punctuatedwith earlier chronic complications [7–
9] and frequent postprandial hyperglycemia [10]. These and
other clinical features must be recognized and factored into
lifestyle recommendations in order to tailor management to
individual needs and improve the effectiveness of preventive
and therapeutic efforts at the primary care level.
2. Methods and Materials
The universal tDNA template for patients with prediabetes
and T2D was established by an international task force of
experts during a two-year process that included planning
and developmental meetings, evidence collection and review,
consensus building, and algorithm construction and face
validation [11]. The initial global template was designed for
simplicity, flexibility, and cultural modification. A compara-
ble process was used by an appointed Malaysian task force
to adapt the algorithm to meet the needs of practitioners
and patients in Malaysia. The regional version emerged
through themodification of general tDNA recommendations
to account for cultural, lifestyle, food, diet, and genetic
differences that exist among the Malaysian people.
2.1. Perspectives Unique toMalaysia. Among themajor ethnic
groups inMalaysia, Indians (24.9% in 2011 and 19.9% in 2006)
had the highest prevalence of T2D, followed byMalays (16.9%
in 2011 and 11.9% in 2006) and Chinese (13.8% in 2011 and
11.4% in 2006) [3, 4]. These epidemiologic differences could
be due to the genetic makeup, diet, and cultural variants
among these major ethnic groups.
The overall prevalence of abdominal obesity in Malaysia,
measured by waist circumference, has been reported between
55.6% and 57.4% [13, 14]. Epidemiologic studies investigating
abdominal obesity in Malaysia have consistently shown an
ethnic trend similar to that seen inT2Dwith prevalence being
highest among Indians (65.5–68.8%), followed by Malays
(55.1–60.6%), Chinese (49.5–51.1%), and other indigenous
groups (44.9–48.3%) [13, 14]. The prevalence of abdominal
obesity is increased among patients with T2D and is observed
in 75% of T2D patients in Malaysia. Moreover, in the
DiabCare Malaysia 2008 study, the most recent study in an
ongoing initiative to monitor diabetes control in Malaysia,
undesirable waist circumference was reported in a higher
proportion of women (≥80 cm in 89.4%) than men (≥90 cm
in 73.7%) with T2D [15].The study patients with T2D, 72% of
whom were obese, had a mean BMI of 27.8 kg/m2.
Glycemic control in Malaysia continues to deteriorate
despite initiatives by the Ministry of Health to increase
awareness and also expanded accessibility of glycosylated
hemoglobin (A1c) testing across the country. The DiabCare
Malaysia 2008 study reported ameanA1c of 8.66%, compared
with 8.0% [16] in 2003, a mean fasting glucose of 8.0mmol/L,
and an elevated mean postprandial glucose of 12.7mmol/L in
Malaysians with T2D. Furthermore, only 22% of the patients
achieved the glycemic target of A1c <7%, the lowest rate
since 1998 [15]. Data from the online registry database Adult
Diabetes Control andManagement (ADCM) revealed ethnic
differences in glycemic control and complication profiles
amongMalaysians. Chinese patients had the lowestmeanA1c
levels, while Malaysian Indians had the highest [17].
Only 16.4%of theMalaysian patients adhere to the dietary
regimen provided by dietitians [20]. Interestingly, patients
were found to adhere to the advice of “eat lots of food high in
dietary fiber such as vegetables or oats” but found it difficult
to eat five or more servings of fruits and vegetables per
day. Self-care practices among the majority of patients with
suboptimal glycemic control are obviously inadequate. A
large proportion of Malaysian T2D patients consume four or
more meals a day and more than two carbohydrate portions
per snack [21].
The currentMalaysia Clinical PracticeGuidelines (CPGs)
for the management of T2D contain recommendations with-
out any specific reference to glycemia-targeted specialized
nutrition (GTSN), that is, oral nutritional products that
facilitate glycemic control and may be used as meal and/or
snack replacements or supplements as part of the medical
nutrition therapy (MNT) [18].With the increasing prevalence
of prediabetes and T2D and the continued deterioration of
glycemic control among patients in Malaysia, there is a clear
need for a simple MNT algorithmic decision-making tool to
address these issues. This paper summarizes the Malaysian
adaptation of the universal tDNA template [11]. See Figure 1.
Specific Southeast Asian and Asian Indian tDNA versions
have also been published [22, 23].
3. Results: Transcultural Factors for Malaysia
3.1. Assessment of Body Composition and Risk of Disease
Progression. The World Health Organization (WHO) West-
ern Pacific Regional Office and the International Diabetes
Foundation (IDF) define overweight and obesity in Asians
as BMI greater than 23 kg/m2 and 25 kg/m2, respectively
[24]. Lower cutoff values are required for Asian populations
because Asians generally have a higher percentage of intra-
abdominal fat compared with Caucasians of the same age,
sex, and BMI [25]. Furthermore, Asian populations have
higher cardiovascular and T2D risk factors than Caucasians
at any BMI level [25, 26], thereby highlighting the rationale
for defining Asian-specific cutoff values for anthropometric
measures.
The Malaysian CPG for the management of obesity
categorizes overweight as BMI of 23.0–27.4 kg/m2 and obesity
as BMI of 27.5 kg/m2 and above [28]. Waist circumference
cutoff values for abdominal obesity are 90 cm for men and
80 cm for women [24]. Similarly, these cutoff values are also
found in the CPG for the management of T2D in Malaysia
[12] and are used as the standard throughout this paper.
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(1) Ethnocultural lifestyle input:
Geographic location and ethnocultural classifications
(2) Individual risk assessment:
Family history of high-risk dietary patterns and premature cardiovascular disease, less than recommended physical activity,
abnormal anthropometrics (BMI/WC/WHR over normal ranges for locale), hypertension, dyslipidemia, any cardiovascular event,
any liver disease, microalbuminuria over normal range, risky alcohol intake, and any sleep disturbance, and any chronic illness
Low risk High risk
(3) General recommendations:
Counseling, physical activity, and healthy eating consistent with
(4) Overweight/obesity (5) Hypertension (6) Dyslipidemia
Lipid-modifying diet
(7) Chronic kidney disease
Protein restricted diet:
-Stage 3–5 or greater: 0.6–0.8 g/kg
with adequate energy intake
(30–35 kcal/kg/day)
Antihypertensive diet consistent
with sodium restriction
At goal
(9) Maintain physical activity and MNT
Not at goal
(10) Intensify physical activity and MNT
(8) Follow-up evaluation (1–3 months):
History, physical (anthropometrics, blood pressure); chemistries
(glucose, A1c, lipids, urinary albumin/creatinine, and liver enzymes);
urinalysis
-Sodium
current clinical practice guidelines or evidence 
Physical activity consistent with guidelines;
weight loss consistent with guidelines;
MNT consistent with guidelines;
GTSN caloric supplementation or
replacement consistent with options and
strategies 
<2.4 g/day 
<2, 400mg/day
See text and tables throughout this report for additional information and clarifications
Figure 1: Transcultural Diabetes Nutrition Algorithm (tDNA): Malaysian application.
3.2. Physical Activity in T2D Management. Physical activity
and exercise have been shown to lower blood glucose levels,
improve glucose and insulin utilization, and improve carbo-
hydratemetabolism [29, 30]. Benefits of physical activity have
been demonstrated in both Caucasian and Asian patients
with T2D [31–34]. The Malaysian CPG for the management
of T2D recommends physical activity as an integral feature
in every stage of T2Dmanagement [12]. These recommenda-
tions are echoed in theMalaysian tDNA application (Table 1).
3.3. MNT and Weight Loss in T2D Management. MNT plays
an integral role in T2D management and indeed is rec-
ommended by the American Diabetes Association as an
important component of individual weight loss programs for
T2D patients [35]. The benefits of MNT on glycemic control
in Asians with prediabetes and T2D have been demonstrated
in clinical trials [36–39]. On-site registered dietitian-led
management of MNT has been shown to improve glycemic
control in poorly-managed patients with T2D in primary care
clinics in Taiwan. Patients with A1c levels ≥7% who received
on-site diabetic self-management education had significantly
greater improvements in fasting plasma glucose and A1c
levels after one year than control subjects or subjects with
A1c levels <7% [36]. A lifestyle intervention that includes
MNT was found to be effective in preventing or delaying the
development of T2D in middle-aged Japanese patients with
impaired glucose tolerance [40, 41].
TheMalaysianDietitians’ Association (MDA) has formed
an expert committee, comprising dietitians from primary
care, hospitals, and academia, to compose MNT recommen-
dations for T2D.The first version was published in 2005 [42]
and updated in 2013 [43]. Building on the MNT guidelines
recommended by the MDA, the Malaysian CPG for the
management of T2D, and taking into consideration similar
Malaysian CPGs for hypertension and dyslipidemia, this
panel recommends the nutritional considerations outlined in
Table 2 [12, 18, 19].
Weight loss is an important therapeutic objective for
T2D patients to reduce insulin resistance. Moderate weight
loss of just 5–10% of body weight in patients with T2D
has been shown to decrease insulin resistance and improve
other metabolic risk factors [38, 44, 45]. GTSN formulae
are a component of MNT that contain nutrients to facilitate
weight management and glycemic control. These formulae
are available in Malaysia and may be utilized with nutritional
counseling asmeal and/or snack replacements for overweight
and obese patients and those with suboptimal glycemic
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Table 1: Physical activity guidelines for the management of type 2
diabetesa [12].
Frequency
Exercise 5 days a week with
no more than 2 consecutive
days without physical
exercise
All patients Intensity andtype
(i) Moderate-intensity
activities include walking
down stairs, cycling, fast
walking, doing heavy
laundry, ballroom dancing
(slow), noncompetitive
badminton, and
low-impact aerobics
(ii) Vigorous activities
include jogging, climbing
stairs, football, squash,
tennis, swimming, jumping
rope, and basketball
Duration
150min per week of
moderate-intensity aerobic
physical activity and/or at
least 90min per week of
vigorous aerobic physical
activity
Overweight or obese patients
(BMI > 23)
Gradually increase physical
activity to 60–90minutes
daily for long-term major
weight loss
BMI: body mass index.
aPatients should be assessed for complications that may preclude vigorous
exercise. Age and previous physical activity level should be considered.
Table 2: Nutrition guidelines for themanagement of type 2 diabetes
[12, 18, 19].
Calories
For overweight and obese individuals, a reduced
calorie diet of 20–25 kcal/kg body weight is
recommended to achieve a weight loss of 5–10%
of initial body weight over a 6-month period
Carbohydrate 45–60% daily energy intake
Protein 15–20% daily energy intake
Fat 25–35% daily energy intake
Saturated fat Less than 7% of total calories
Cholesterol Less than 200mg/day
Fiber∗ 20–30 g/day
Sodium <2,400mg/day
∗Should be derived predominantly from foods rich in complex carbohy-
drates including grains (especially whole grains), fruits and vegetables.
control, including persons with high insulin requirements.
These formulae are also indicated as a supplementary nutri-
tion for patients with diabetes and acute concurrent illness
who are unable to maintain optimal nutrition due to reduced
appetite and calorie intake. Recommendations for the use of
meal replacements will be incorporated in the revised MNT
guidelines from the MDA.
3.4. Nutritional Management of Patients with Concomitant
Hypertension, Dyslipidemia, and/or Chronic Kidney Disease
(CKD). Data from the ADCM’s online registry database
showed that as many as 57% of the Malaysian patients with
T2D experience concomitant hypertension [46]. Among the
ethnic groups in Malaysia, more Malay patients (62.3%)
have concomitant hypertension than Chinese (19.6%) or
Indian (17.0%) patients. In patients with T2D, hypertension is
defined as blood pressure >130/80mmHg on two readings 2-
3 weeks apart [12]. Pharmacotherapy for hypertension should
be initiated in patients with T2D when the blood pressure is
persistently >130mmHg systolic and/or >80mmHg diastolic
[12]. For patients with concomitant hypertension, salt intake
should be restricted to <6 g/day (sodium 2 g) [18].
The ADCM also revealed that as many as 38% of the
patients with T2D in Malaysia suffer from concomitant dys-
lipidemia [47]. Malays were more likely to have uncontrolled
low-density lipoprotein cholesterol (LDL-C) and triglyc-
erides compared with Chinese and Indians; however, Indians
were twice as likely to have inadequate high-density lipopro-
tein cholesterol compared with Malays [47]. A recent study
that investigated the ethnic differences in lipid metabolism
among Malaysian patients with T2D demonstrated that
Malays had significantly higher serum levels of glycoxidation
and lipoxidation products compared with those of Chinese
and Indian patients [48]. For T2D patients with dyslipidemia,
lifestyle modification focusing on the reduction of saturated
fat (<7% of total calories), trans fat (avoid), and choles-
terol (<200mg/day) intake has been recommended [12, 19].
In accordance with the Malaysian CPG for dyslipidemia,
patients over the age of 40 without overt cardiovascular
disease (CVD) should be treated with lipid lowering drugs,
regardless of the baseline LDL-C levels, while all patients with
overt CVD, irrespective of age, should be treated with lipid
lowering drugs [19].
For T2D patients with concomitant CKD, limited protein
intake and daily sodium <2400mg are recommended. For
those with CKD stages 3–5, daily protein should be limited
to 0.6–0.8 g/kg in a diet with adequate energy intake (30–35
kcal/kg/day) [49].
4. Conclusions
The following recommendations, statements, figures, tables,
and graphs represent the conclusions of the Malaysian tran-
scultural Diabetes Nutrition Algorithm (tDNA) task force
and constitute the current Malaysian tDNA application,
which accommodates local differences in lifestyle, foods, and
customs and incorporates established local Clinical Practice
Guidelines (CPGs) to meet the needs and preferences of type
2 diabetes (T2D) patients in Malaysia.
Recommendation 1. Medical nutrition therapy (MNT) is an
integral component of the management of T2D and must
be prioritized in view of poor glycemic control among
patients in Malaysia. Individualized care plans are essential
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Table 3: Glycemia-targeted specialized nutrition (GTSN) for the
management of prediabetes and type 2 diabetes.
Overweight (BMI > 23 kg/m2) or
obese (BMI > 27.5 kg/m2)
Use meal and/or snack
replacementsa as part of a
meal plan to reduce total
calorie intake
(i) Calorie reduction of
500–1000 calories per day
(to lose 0.5–1.0 kg per
week), using 1-2 servings of
a GTSN formulab to replace
250–500 calories from
meals
(ii) Reassess every
1–3months
Normal weight
(BMI 18–23 kg/m2)
Controlled
diabetes
(A1c ≤ 6.5%c)
The use of meal
replacements should be
based on clinical judgment
and individual assessmentd
Uncontrolled
diabetes
(A1c > 6.5%c)
Use 1-2 servings of a GTSN
formula per day to be
incorporated into a meal
plan
Underweight (BMI < 18 kg/m2)
Use 1–3 servings of a GTSN
formula per day as
supplementation based on
clinical judgment and
individual assessment of
desired rate of weight gain
and clinical tolerance
BMI: body mass index; A1c: glycosylated hemoglobin; GTSN: glycemia-
targeted specialized nutrition.
Recommendations were rated and assigned numerical and alphabetical
descriptors according to levels of scientific substantiation provided by the
2010 American Association of Clinical Endocrinologists protocol for the
development of Clinical Practice Guidelines [27].
aMeal and snack replacements are nutritional products used as replacement
formeals or snacks to replace calories in the diet. It is suggested that products
used should meet the American Diabetes Association nutritional guidelines.
bGlycemia-targeted specialized nutrition formulas are complete and bal-
anced products with at least 200 calories per serving used as part of a meal
plan to help control calorie intake and achieve glycemic control.
cGlycemic (A1c) targets should be individualized for each patient based on
local CPGs.
dTo avoid hypoglycemia or postprandial hyperglycemia, individuals who
may have muscle mass and/or function loss and/or micronutrient deficiency
may benefit from a nutrition supplement. Individuals who need support with
weight maintenance and/or a healthy meal plan could benefit from meal
replacement.
in order to increase adherence and compliance with MNT
recommendations.
Recommendation 2. Personalized nutrition counseling by
a dietitian is recommended and should be individualized
according to personal nutritional needs, concomitant disease,
severity of T2D, cultural preferences, and patient coopera-
tion. If access to a dietitian is not possible, all newly diagnosed
patients should receive basic nutrition and dietary counseling
from either doctors or diabetes educators.
Recommendation 3. Values for bodymass index (BMI) cutoffs
in the Malaysian CPGs are recommended for use in the
Malaysian tDNA.
Recommendation 4. TheMalaysian CPG for the management
of T2D recommends physical activity as an integral feature
in every stage of T2Dmanagement [12]. These recommenda-
tions are adopted in the Malaysian tDNA (Table 1).
Recommendation 5. Overweight and obese individuals should
achieve a weight loss of 5–10% of the initial body weight over
a 6-month period (Table 2).
Recommendation 6. The nutritional recommendations out-
lined in Table 2 (adapted from the Malaysian Dietitians’
Association’sMNT guidelines and theMalaysian CPG for the
management of T2D) should be implemented as part of the
Malaysian tDNA.
Recommendation 7. Patients with T2D and concomitant
hypertension should limit salt intake to <6 g/day (sodium
2 g). Those with concomitant chronic kidney disease (CKD)
should limit protein intake, especially those with CKD stages
3–5 (daily protein of 0.6–0.8 g/kgwith adequate energy intake
of 30–35 kcal/kg/day).
Recommendation 8. Lifestyle modification focusing on the
reduction of saturated fat (<7% of total calories) and choles-
terol (<200mg/day), as well as the avoidance of trans-fat,
is recommended for patients with T2D and concomitant
dyslipidemia.
Recommendation 9. The use of meal replacements should be
based on clinical judgment and individual assessment. For
patients who are overweight,meal and/or snack replacements
are recommended as part of meal plans to reduce total
calorie intake (Table 3). For patients of normal weight with
uncontrolled T2D, 1-2 servings of a GTSN formula per day,
incorporated into a meal plan as meal or snack replace-
ment, are recommended. For underweight individuals, 1–
3 servings of a GTSN formula per day are recommended
as supplementation based on the clinical judgment and
individual assessment of desired rate of weight gain and
clinical tolerance.
Recommendation 10. To provide support and motivate
patients to comply with MNT, monthly follow-ups are rec-
ommended for patients with poorly-controlled T2D and for
those who are at high risk of complications. For patients
with well-controlled T2D, regular follow-up every 3 months
is recommended.
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